摘要
Background： High-dose chemotherapy followed by autologous stem cell transplantation （ASCT） is a promising approach tbr lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide （ICE）-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma. Methods： From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival （OS） and progression free survival （PFS） were evaluated by univariate analysis. Results： The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stein cell collection of at least 2.0 ×10^6, CD34^＋ cells/kg and 68% had at least 5 × 10^6, CD34^＋ cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively. Conclusion： ICE is a powerful regimen for stem cell mobilization in patients with lymphomas.
Background： High-dose chemotherapy followed by autologous stem cell transplantation （ASCT） is a promising approach tbr lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide （ICE）-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma. Methods： From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival （OS） and progression free survival （PFS） were evaluated by univariate analysis. Results： The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stein cell collection of at least 2.0 ×10^6, CD34^＋ cells/kg and 68% had at least 5 × 10^6, CD34^＋ cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively. Conclusion： ICE is a powerful regimen for stem cell mobilization in patients with lymphomas.
